Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
iRadimed Corporation reports news on its MRI-compatible medical-device business, including non-magnetic IV infusion pump systems, patient vital signs monitoring systems, accessories, disposables and related services sold to hospitals and acute care facilities. Company updates often describe financial results, revenue and earnings guidance, cash generation, and regular or special cash dividends.
IRMD news also covers product activity for systems such as the 3880 MRI-compatible patient vital signs monitor and the next-generation 3870 MRI-compatible IV infusion pump, along with investor conference participation and recognition tied to growth and financial performance.
Iradimed (NASDAQ: IRMD) reported second quarter 2026 revenue of $20.5 million, up 0.5% year over year, with GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46. Net income declined to $5.2 million, down 10% from the prior-year quarter, and gross margin fell to 74% from 78%.
For the first six months of 2026, revenue rose 6% to $42.4 million, GAAP net income increased 5% to $11.0 million, and non-GAAP net income grew 5% to $12.2 million. Operating cash flow was $5.9 million in Q2 and $14.2 million year-to-date. The company reaffirmed full‑year 2026 guidance of $91.0–$96.0 million in revenue, GAAP EPS of $1.90–$2.05, and non-GAAP EPS of $2.09–$2.24, and declared a regular quarterly cash dividend of $0.20 per share, payable August 28, 2026.
Iradimed (NASDAQ: IRMD) will release its 2026 second quarter financial results before the market opens on Friday, July 31, 2026. Management will host a conference call at 11:00 a.m. Eastern Time the same day, with access via online registration, live webcast, and a post-call recording on the company’s website.
Iradimed (NASDAQ: IRMD) announced that President and CEO Roger Susi and CFO Jack Glenn will attend the Goldman Sachs 47th Annual Global Healthcare Conference, held June 8–10, 2026, at the Loews Miami Beach Hotel in Miami Beach, Florida.
Interested investors can contact their Goldman Sachs representative to arrange one-on-one meetings with Iradimed management during the conference.
IRADIMED (NASDAQ: IRMD) reported Q1 2026 revenue of $22.0 million, up 13% year‑over‑year, GAAP diluted EPS of $0.45 (record) and non‑GAAP diluted EPS of $0.49. Operating income was $7.2 million and cash flow from operations was $8.3 million. The board declared a regular quarterly cash dividend of $0.20 per share payable May 29, 2026. The company launched its next‑generation 3870 MRI-compatible IV infusion pump with strong early orders and reaffirmed full‑year 2026 guidance: revenue $91.0–$96.0M, GAAP EPS $1.90–$2.05, non‑GAAP EPS $2.06–$2.21.
IRADIMED (NASDAQ: IRMD) will release its Q1 2026 financial results before market open on May 1, 2026. Management will host a conference call the same day at 11:00 a.m. ET to discuss results and answer questions. Registration is required for dial-in details and a webcast will stream live; a recording will be posted after the call.
IRADIMED CORPORATION (NASDAQ: IRMD) will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. CFO Jack Glenn will conduct one-on-one investor meetings during the virtual event to discuss corporate strategy and investor relations.
IRADIMED CORPORATION (NASDAQ: IRMD) will participate in the 38th Annual Roth Conference. CEO Roger Susi and CFO Jack Glenn will hold one-on-one investor meetings at the Ritz-Carlton, Laguna Niguel, CA, on March 22 and March 24, 2026.
This presentation provides an opportunity for investors to meet senior management and discuss strategy and financial priorities face-to-face.
IRADIMED (NASDAQ: IRMD) reported record Q4 2025 revenue of $22.7 million (+17% YoY) and GAAP diluted EPS of $0.50 (non-GAAP $0.54). Full‑year 2025 revenue was $83.8 million (+14%) with GAAP EPS $1.75 (non‑GAAP $1.93). The board raised the regular quarterly cash dividend to $0.20 per share, payable March 6, 2026. Management expects 2026 revenue of $91.0–$96.0 million and provided Q1 2026 and full‑year GAAP and non‑GAAP EPS ranges. The company noted completion of FDA 510(k) steps and a product rollout for the next‑generation Model 3870 pump in 1H–2H 2026.
IRADIMED (NASDAQ: IRMD) will release its 2025 fourth quarter and full year financial results before the market opens on Tuesday, February 10, 2026.
Company management will host a conference call the same day at 11:00 a.m. Eastern Time, available by registration for dial-in details and via a real-time webcast. A recording will be posted on the investor website after the call.
iRadimed (NASDAQ: IRMD) announced a special cash dividend of $0.50 per share, payable on December 30, 2025 to stockholders of record at the close of business on December 17, 2025.
The Board said the dividend follows strong financial results, including 17 consecutive quarters of record revenue and a cash and cash equivalents balance of $56.5 million at the end of Q3 2025. Management cited excess cash beyond needs for operations and the transition to a new manufacturing facility, and noted ongoing investments such as commercialization of the 3870 MRI IV pump.
The Board emphasized future dividends remain at its sole discretion and are subject to financial condition, cash flows, capital requirements and other factors.